Clinical Trials

Multiple Myeloma

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05050097 2026-04-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

500 enrolled

Phase 3 Active not recruiting

Multiple Myeloma

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05675449 2026-04-13

MagnetisMM-20

59 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Multiple Myeloma, Recurrence

NCT06413498 2026-03-27

iMMagine-3

450 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

508 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

440 enrolled

Multiple Myeloma, Neoplasms

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03275285 2026-02-09

IKEMA

302 enrolled 38 charts 2 FDA

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

15 enrolled 15 charts

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Phase 2 Active not recruiting

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

118 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

200 enrolled

Multiple Myeloma

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT03934684 2025-08-06

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4 Completed

101 enrolled 11 charts

Phase 2 Active not recruiting

Multiple Myeloma

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

19 enrolled

LymphoidOther hematologic neoplasm

Multiple Myeloma, Recurrence

NCT02303821 2025-06-04

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Completed

141 enrolled 37 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03158688 2025-05-09

CANDOR

466 enrolled 33 charts 3 FDA

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

36 enrolled 17 charts

265 enrolled 21 charts 5 FDA

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 3 FDA

Multiple Myeloma

NCT03871829 2025-03-30

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

88 enrolled 21 charts

Phase 2 Active not recruiting

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

LymphoidOther hematologic neoplasmPlasma cell

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03859427 2024-08-13

ARROW2

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

45 enrolled

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

45 enrolled

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Phase 3 Active not recruiting

Multiple Myeloma

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT01568866 2022-11-14

ENDEAVOR

929 enrolled 21 charts

Multiple Myeloma

NCT01677858 2022-09-23

CHAMPION 1

Phase 1/2 Completed

116 enrolled 28 charts

Multiple Myeloma

NCT02412878 2022-09-23

ARROW

478 enrolled 17 charts

Multiple Myeloma

NCT01080391 2022-09-21

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

792 enrolled 18 charts

Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

136 enrolled

Multiple Myeloma

NCT03029234 2022-05-25

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

126 enrolled 30 charts

Multiple Myeloma, Recurrence

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

13 enrolled

Multiple Myeloma

NCT01962792 2021-12-21

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

84 enrolled 14 charts

Multiple Myeloma

NCT02036502 2021-04-08

MK-3475-023

77 enrolled 23 charts

Multiple Myeloma

NCT03512353 2021-01-08

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

7 enrolled 32 charts